TNF Pharmaceuticals: A Promising Player in the TNF Inhibitor Market

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has announced positive topline results from a Phase 2a study of its lead drug candidate, MYMD-1® (isomyosamine), for the treatment of sarcopenia in elderly patients. The company is set to initiate a Phase 2b study in early 2025, further expanding its clinical trials and solidifying its position in the TNF inhibitor market.

Sarcopenia, the progressive loss of muscle mass and strength primarily due to aging, affects at least 50 million people worldwide, with the prevalence projected to reach over 200 million in the next four decades. The sarcopenia treatment market is estimated to be $3.07 billion in 2024, with an expected CAGR of 4.48% to reach $4.02 billion by 2029. However, the broader TNF inhibitor market is significantly larger, valued at $39.7 billion in 2024 and expected to grow at a CAGR of 3.6% to reach $47.3 billion by 2029.

MYMD-1, a novel plant alkaloid small molecule, has shown promising results in regulating the immuno-metabolic system by modulating numerous pro-inflammatory cytokines, including TNF-alpha (TNF-α). In the Phase 2a study, once daily oral doses of MYMD-1 resulted in significant decreases in several biomarkers attributed to chronic inflammation, including TNF-α (P=0.008), Interleukin-6 (IL-6) (P=0.03), and soluble TNF-α receptor 1 (sTNFR1) (P=0.02) at various timepoints throughout the 28-day treatment period. No serious adverse events were reported, indicating a strong safety profile for the drug.

If approved, MYMD-1 would become the first oral TNF-α inhibitor, offering a more convenient and potentially safer treatment option for patients with sarcopenia and other TNF-α related conditions. The estimated $40 billion TNF inhibitor market, along with the growing prevalence of sarcopenia and other age-related diseases, highlights the significant potential for MYMD-1 to address an unmet medical need and provide substantial patient benefits.



Moreover, TNF Pharmaceuticals' strategic equity investment from Prevail Partners, LLC, priced at a 20% premium to the Company's 30-trading days VWAP, and the engagement of global full-service Clinical Research Organization (CRO) Prevail InfoWorks, Inc., further strengthen the company's financial and operational capabilities. With fully funded clinical trials for the next two years, TNF Pharmaceuticals is well-positioned to advance its comprehensive MYMD-1 platform in longer-term clinical trials and future studies in multiple conditions associated with immunometabolic dysregulation.

In conclusion, TNF Pharmaceuticals' positive clinical data supports the expansion of its clinical trials for MYMD-1 in sarcopenia and other TNF-α related conditions. With a strong safety profile, the potential to address an unmet medical need, and a promising market opportunity, MYMD-1 has the potential to become a consequential therapeutic solution for patients not served by current TNF-alpha inhibitors. As the company continues to advance its clinical trials and secure centers of excellence for enrollment, investors should keep a close eye on TNF Pharmaceuticals' progress in the TNF inhibitor market.